Illumina (NASDAQ:ILMN) Reaches New 1-Year Low – What’s Next?

Illumina, Inc. (NASDAQ:ILMN)’s stock price reached a new 52-week low during trading on Tuesday . The company traded as low as $99.33 and last traded at $100.01, with a volume of 1715757 shares. The stock had previously closed at $100.24.

Wall Street Analyst Weigh In

A number of research firms have commented on ILMN. Piper Sandler raised their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Robert W. Baird raised their price target on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Barclays cut shares of Illumina from an “equal weight” rating to an “underweight” rating and reduced their price target for the stock from $130.00 to $100.00 in a report on Monday, February 10th. Guggenheim reduced their price target on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Finally, Canaccord Genuity Group reduced their price objective on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $159.45.

Illumina Trading Down 5.6 %

The firm has a market cap of $15.40 billion, a P/E ratio of -12.66, a price-to-earnings-growth ratio of 1.67 and a beta of 1.10. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm’s 50-day simple moving average is $128.97 and its 200 day simple moving average is $134.16.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Institutional Trading of Illumina

Hedge funds have recently added to or reduced their stakes in the stock. Versant Capital Management Inc raised its position in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the period. Golden State Wealth Management LLC bought a new stake in shares of Illumina in the fourth quarter valued at approximately $32,000. Fourth Dimension Wealth LLC bought a new stake in shares of Illumina in the fourth quarter valued at approximately $40,000. Assetmark Inc. raised its position in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina in the fourth quarter valued at approximately $45,000. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.